文章：

吉西他滨与达卡巴嗪联合治疗晚期软组织肉瘤的获益应用：真实世界数据

Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data

原文发布日期：8 January 2024

DOI: 10.3390/cancers16020267

类型: Article

开放获取: 是

英文摘要：

Background: The combination of gemcitabine and dacarbazine has exhibited efficacy in terms of progression-free survival (PFS) and overall survival (OS) for aSTSs, albeit without robust confirmation from larger clinical trials. Methods: We conducted a retrospective study in a single institution involving aSTS patients treated with gemcitabine and dacarbazine. Results: 95 patients were assessed, pointing to a benefit in PFS of 3.5 months and an OS of 14.2 months. Patients with translocated histotypes had better PFS, while those with platelet–lymphocyte ratios (PLRs) surpassing a specific threshold or lower albumin levels had poorer overall survival. Conclusions: This study validates previous findings from three phase I–II trials, affirming the utility of this treatment approach in routine clinical practice.

摘要翻译： 

背景：吉西他滨与达卡巴嗪联合用药方案在延长晚期软组织肉瘤（aSTSs）患者的无进展生存期（PFS）和总生存期（OS）方面已显示出疗效，但尚未通过大规模临床试验获得有力证实。方法：我们在单一机构开展了一项回顾性研究，纳入接受吉西他滨联合达卡巴嗪治疗的晚期软组织肉瘤患者。结果：共评估95例患者，其PFS获益达3.5个月，OS达14.2个月。具有易位组织学亚型的患者PFS更优，而血小板-淋巴细胞比值（PLR）超过特定阈值或白蛋白水平较低的患者总生存期较差。结论：本研究验证了此前三项I-II期临床试验的结果，证实了该治疗方案在常规临床实践中的应用价值。

原文链接：

Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data